Skip to main content
SpringerLink
Log in

CD20 monoclonal antibodies-related tumour lysis syndrome

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Xia S, et al. Tumor Lysis Syndrome with CD20 Monoclonal Antibodies for Chronic Lymphocytic Leukemia: Signals from the FDA Adverse Event Reporting System. Clinical Drug Investigation : 27 Sep 2023. Available from: URL: http://doi.org/10.1007/s40261-023-01308-0

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

CD20 monoclonal antibodies-related tumour lysis syndrome. Reactions Weekly 1977, 7 (2023). https://doi.org/10.1007/s40278-023-47081-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-47081-6

Search

Navigation